



Novartis India Limited
Registered Office:
Inspire BKC
Part of 601 & 701
Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051
Maharashtra, India
Tel +91 22 50243000
Fax +91 22 50243010
Email: india.investors@novartis.com
CIN No. L24200MH1947PLC006104
Website: www.novartis.in

December 4, 2019

The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Sub.: Disclosure of related party transactions for the half year ended on September 30, 2019

Ref.: 1. Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

2. Scrip Code: 500672

Dear Sir/ Madam,

Apropos the subject matter quoted above, please find enclosed herewith the disclosure of Related Party Transactions on a standalone basis, in format as specified in the relevant accounting standards for the half year ended on September 30, 2019.

The above is for your information and the same is also available on the Company's website i.e. www.novartis.in

Thanking you

Yours sincerely,

For Novartis India Limited

Trivikram Guda
Company Secretary &
Compliance Officer

(b) Fellow SubsidiariesHalf year ended 30 Sep 2019
in ₹ million

Purchases of Stock-in-Trade	
Novartis Pharma AG	541.4
	<u>541.4</u>
Sale of Services	
Novartis Healthcare Private Limited	37.2
Novartis Pharma AG	15.0
Sandoz Private Limited	13.7
	<u>65.9</u>
Commission Income	
Novartis Healthcare Private Limited	137.2
	<u>137.2</u>
Services Availed	
Novartis Healthcare Private Limited	17.3
Novartis Pharma AG	0.9
	<u>18.2</u>
Purchase of Restricted Shares of Novartis AG on behalf of employees of the Company by	
Novartis Holding AG	3.1
	<u>3.1</u>
Expenses paid by related party on behalf of the Company	
Novartis Healthcare Private Limited	2.1
	<u>2.1</u>
Expenses paid by the Company on behalf of the related party	
Sandoz Private Limited	0.002
	<u>0.002</u>



	Half year ended 30 Sep 2019 in ₹ million
Balances as at the half year end -	
Outstanding Receivables	
Novartis Healthcare Private Limited	104.9
Novartis Pharma AG	1.4
Novartis Holding AG	4.6
Sandoz Private Limited	6.2
	117.1

	Half year ended 30 Sep 2019 in ₹ million
Outstanding Payables	
Novartis Healthcare Private Limited	889.1
Novartis Pharma AG	292.6
	1,181.7

(c) Post Employment Benefit Plans of Novartis India Limited

	Half year ended 30 Sep 2019 in ₹ million
Contribution to In-house Trust for Post Employment Benefits	
Novartis India Limited Employees' Provident Fund	66.4

(d) Key Management Personnel Compensation

	Half year ended 30 Sep 2019 in ₹ million
Short-term employee benefits	8.9
Post-employment benefits	0.6
Commission/ Sitting Fees to Independent Directors	0.9
Total compensation	10.3

Notes:

1) No amounts have been written off/provided for or written back in respect of amounts receivable from or payable to the related parties.

2) Outstanding balances at the half year-end are unsecured and interest free and settlement occurs in cash.

